Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Infranity in connection with the acquisition of Nordic Re-Finance AB
Mandate

Vinge advises Infranity in connection with the acquisition of Nordic Re-Finance AB

January 20, 2025 Employment and Benefits M&A Data protection and processing of personal data FDI Intellectual Property Corporate Tax Banking and Finance

Vinge has advised Infranity, a private equity firm specializing in infrastructure investments, in connection with its acquisition of a majority stake in Nordic Re-Finance AB, a Scandinavian locomotives lessor. The acquisition brings ambitious development plans for Nordic Re-Finance AB, including expansion into new geographical areas.

The transaction is subject to regulatory approvals and is expected to close in Q1 2025.

Vinge’s team consisted of among other Matthias Pannier, Ulrich Ziche, Robin Sultani and Sara Hammond (M&A), Calle Tengwall Pagels and Julia Gudmundsson (Banking and Finance, Jolene Reimerson, Christoffer Nordin, Katja Häglund and Nicklas Thorgerzon (Commercial Contracts, IT and GDPR), Victor Ericsson, Erik Kochbati, Tobias Fleischer, Ellenor Eckerborn and Marcus Svärd (Tax), Alice Göransson and Gulestan Ali (Employment), Tobias Kempas and Rebecka Målquist (IP), Daniel Wendelsson, Alva Chambert and Martin Hammarskiöld (FDI) and Julia Ulander Kull (Transaction Support).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025